Stocks
Allogene Therapeutics (ALLO) EBITDA margin US GAAP (year values) |
|||||||||
| FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -148.8% | -205 924% | -329 543% | -1 106 032% | ||||
| Changes by years, y/y, % | -205 775pp | -123 619pp | -776 489pp | +1 851.7% | |||||
Allogene Therapeutics. EBITDA margin, %
Allogene Therapeutics. EBITDA margin, changes, pp
Allogene Therapeutics (ALLO) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | FY2026Q2 | LTM ? | |||
| EBITDA margin, % | ? | -855.4% | ||||||
| Changes by years, y/y, % | ||||||||
| Changes by quarters, q/q, % | ||||||||
